1.Xing H, Gao MS, Wang YX, Zhang X, Shi J, Wang X, Liu X, Ma Q, Kong X, Yang C, Ding J*, Meng L*. Genome-wide gain-of-function screening identifies EZH2 mediating resistance to PI3Kα inhibitors in esophageal squamous cell carcinoma. Clin Transl Med. 2022;12:e835
2.Zhang X, Wang YX, Meng L*. Comparative genomic analysis of esophageal squamous cell carcinoma and adenocarcinoma: New opportunities towards molecularly targeted therapy. Acta Pharmaceutica Sinica B. 2022; 12( 3): 1054-1067
3.Chen ZQ, Cao ZR, Wang Y, Zhang X, Xu L, Wang YX, Chen Y, Yang CH, Ding J*, Meng LH*. Repressing MYC by targeting BET synergizes with selective inhibition of PI3Kα against B cell lymphoma. Cancer Lett. 2022 ;524:206-218.
4.Sun P, Zhang X, Wang RJ, Ma QY, Xu L, Wang Y, Liao HP, Wang HL, Hu LD, Kong X*, Ding J*, Meng LH*. PI3Kα inhibitor CYH33 triggers antitumor immunity in murine breast cancer by activating CD8 + T cells and promoting fatty acid metabolism. J Immunother Cancer. 2021; 9(8):e003093.
5.Wang YX, Zhang X, Ma QY, Hu LD, Zhang X, Wang Y, Xu L, Yang CH, Tan C, Kong XY, Ding J*, Meng LH*. Adaptive resistance to PI3Kα-selective inhibitor CYH33 is mediated by genomic and transcriptomic alterations in ESCC cell. Cell Death Dis. 2021;12(1):85.
6.Liu XL, Wang BB, Wang Y, Wang YX, Yang CH, Tan C, Zhang X, He QJ, Ding J*, Meng LH*. Unbiased screening reveals that blocking exportin 1 overcomes resistance to PI3Kα inhibition in breast cancer. Signal Transduct Target Ther. 2019 Nov 22;4:49.
7.Shi JJ, Xing H, Wang YX , Zhang X, Zhan QM, Geng MY, Ding J*, Meng LH*. PI3Kα Inhibitors Sensitize Esophageal Squamous Cell Carcinoma to Radiation by Abrogating Survival Signals in Tumor Cells and Tumor Microenvironment. Cancer Lett. 2019;459:145-155
8.Liu XL, Liu JL, Xu YC, Zhang X, Wang YX, Qing LH, Guo W, Ding J*, Meng LH*. Membrane metallo-endopeptidase mediates cellular senescence induced by oncogenic PIK3CAH1047R accompanied with pro-tumorigenic secretome. Int J Cancer. 2019; 145:817-829
9.Liu XL, Xu YC, Wang YX, Chen Y, Wang BB, Wang Y, Hu LD, Ma QY, Zhang YC, Sun YM, Gao YL, Yang CH, Ding J*, Meng LH*. Decrease in phosphorylated ERK indicates the therapeutic efficacy of a clinical PI3Kα-selective inhibitor CYH33 in breast cancer. Cancer Lett. 2018;433:273-282.
10.Xu YC, Wang X, Chen Y, Chen SM, Yang XY, Sun YM, Geng MY, Ding J*, Meng LH*. Integration of Receptor Tyrosine Kinases Determines Sensitivity to PI3Ka-selective Inhibitors in Breast Cancer. Theranostics 2017; 7:974-986